Deciphera Pharmaceuticals Stock

Deciphera Pharmaceuticals EBIT

Delisted·Jun 10, 2024

The EBIT of Deciphera Pharmaceuticals (DCPH) as of Jul 28, 2026 is -210.96 M USD. In the previous year, EBIT was -182.72 M USD — a change of 15.45% (lower).

EBIT

-210.96 MUSD

YoY

15.45%

Last updated:

In 2026, Deciphera Pharmaceuticals's EBIT was -210.96 M USD, a 15.45% increase from the -182.72 M USD EBIT recorded in the previous year.

The Deciphera Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
YEAREBIT (undefined USD)
2029 est -
2028 est -
2027 est -
2026 est -
2025 est -
2024 est -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
Access this data via the Eulerpool API

Deciphera Pharmaceuticals Revenue

Deciphera Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
134.04 M USD
-182.72 M USD
-178.93 M USD
Jan 1, 2023
163.36 M USD
-210.96 M USD
-194.94 M USD
Jan 1, 2024 (e)
204.14 M USD
-203.21 M USD
-168.42 M USD
Jan 1, 2025 (e)
271.52 M USD
-271.52 M USD
-132.48 M USD
Jan 1, 2026 (e)
379.79 M USD
-379.79 M USD
-49.19 M USD
Jan 1, 2027 (e)
531.42 M USD
-531.42 M USD
49.68 M USD
Jan 1, 2028 (e)
381.36 M USD
-381.36 M USD
-5.95 M USD
Jan 1, 2029 (e)
610.88 M USD
0.00 USD
134.48 M USD

Deciphera Pharmaceuticals Margins

Deciphera Pharmaceuticals stock margins

The Deciphera Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Deciphera Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Deciphera Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
93.46 %
-136.32 %
-133.49 %
Jan 1, 2023
97.72 %
-129.14 %
-119.34 %
Jan 1, 2024 (e)
97.72 %
-99.54 %
-82.50 %
Jan 1, 2025 (e)
97.72 %
-100.00 %
-48.79 %
Jan 1, 2026 (e)
97.72 %
-100.00 %
-12.95 %
Jan 1, 2027 (e)
97.72 %
-100.00 %
9.35 %
Jan 1, 2028 (e)
97.72 %
-100.00 %
-1.56 %
Jan 1, 2029 (e)
97.72 %
0.00 %
22.01 %

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Deciphera Pharmaceuticals's EBIT

Deciphera Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Deciphera Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Deciphera Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Deciphera Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

EBIT of Deciphera Pharmaceuticals is -210.96 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Deciphera Pharmaceuticals

All Key Metrics — Deciphera Pharmaceuticals